^
Association details:
| Biomarker: | EGFR exon 20 insertion |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug Class: | EGFR inhibitor |
| Direction: | Resistant |
Evidence:
Source:
Title:
Clinical Characteristics of Advanced Non-Small Cell Lung Cancer with EGFR Exon 20 Insertions
Published date:
06/22/2021
Excerpt:
We retrospectively reviewed advanced NSCLC patients with EGFR mutations, including EGFR exon 20 insertions…Additionally, eight patients received anti-PD-1 antibodies and seven patients received EGFR-tyrosine kinase inhibitors (TKIs) in any-line therapy, and their ORR and mPFS were 0%, 25% and 2.2, 3.1 months, respectively. Overall survival was significantly shorter in patients with exon 20 insertions than in those with EGFR major mutations (29.3 vs. 43.4 months, p=0.04).
DOI:
10.21203/rs.3.rs-609572/v1
Source:
Title:
MA04.07 - Comparative Clinical Outcomes for Patients with NSCLC Harboring EGFR Exon 20 Insertion Mutations and Common EGFR Mutations
Published date:
01/12/2021
Excerpt:
Patients with Exon20ins have a worse prognosis compared with patients with cEGFR . Furthermore, EGFR TKI treatment was substantially less effective for patients with Exon20ins, as the risk of disease progression and mortality was higher compared with patients with cEGFR . These findings highlight the need for new treatment options for Exon20ins.
